Barclays’s Azora Therapeutics, Inc. Common Stock AZR Stock Holding History

Barclays’s Portfolio AZR Stock Details AZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.39K	Buy	+1,094	New	+$4.7K	﹤0.01%	4907
2021 Q2	–	Sell	-25	Closed	-$38K	–	4854
2021 Q1	$38K	Buy	+25	New	+$37.8K	﹤0.01%	4255
2019 Q4	–	Hold	0	–	–	–	6304
2019 Q3	–	Hold	0	–	–	–	6663
2019 Q2	–	Hold	0	–	–	–	6899
2019 Q1	–	Hold	0	–	–	–	6971

Other funds holding AZR

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Manchester Capital Management Manchester, Vermont $736M AUM 20.83% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Abound Wealth Management Franklin, Tennessee $537M AUM 14.21% 1-Year Est. Return

Barclays's AZR Position: Q3 2026 in Review

Barclays opened a new position in Azora Therapeutics, Inc. Common Stock (AZR) in Q3 2026: 1,094 shares worth $4.39K. The stake represents ﹤0.01% of the portfolio and ranks #4907 among its holdings. This is a return to the name: Barclays previously reported a position in AZR as recently as Q1 2021.

Barclays first reported a position in AZR in Q1 2021 and has held it in 2 quarters since. The position peaked at $38K in Q1 2021. 7 funds tracked by Wall St. Rank hold AZR as of Q3 2026.

Barclays held 1,094 shares of Azora Therapeutics, Inc. Common Stock worth $4.39K as of Q3 2026.
Azora Therapeutics, Inc. Common Stock was a new Barclays position in Q3 2026.
Azora Therapeutics, Inc. Common Stock made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4907 holding.
Barclays first reported a position in Azora Therapeutics, Inc. Common Stock in Q1 2021 and has held it in 2 quarters since.
Barclays's Azora Therapeutics, Inc. Common Stock position peaked at $38K in Q1 2021.
7 funds tracked by Wall St. Rank held Azora Therapeutics, Inc. Common Stock as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.